VEGF 165 (Homodimer) (Active) Protein

Catalog No. ABIN1589678

This Recombinant protein is produced in Escherichia coli (E. coli). There is 1 publication available.

Quick Overview for VEGF 165 (Homodimer) (Active) Protein (ABIN1589678)

Target: VEGF 165

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Purity: > 95 % by SDS-PAGE. Visualized by silver stain

Product Details

Protein Characteristics: Homodimer

Sequence: APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR

Characteristics: Length (AA): 164
Chromosomal location: 6p12
The ED50 for stimulation of cell proliferation in human umbilical vein endothelial cells by VEGF165 has been determined to be in the range of 1-5 ng/mL.

Endotoxin Level: < 0.1 ng per µg of human VEGF165

Application Details

Comment:

Cytokines & Growth Factors

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: The lyophilized VEGF165 should be reconstituted in 50 mM acetic acid to a concentration not lower than 50 μg/mL. For long term storage we recommend to add at least 0.1% human or bovine serum albumin.

Buffer: 50 mM acetic acid

Storage: -20 °C/-80 °C

Storage Comment: Lyophilized samples are stable for greater than six months at -20 °C to -70 °C. Reconstituted VEGF165 should be stored in working aliquots at -20 °C.

Expiry Date: 6 months

References

Gaumann, Drexler, Lang, Stoeltzing, Diermeier-Daucher, Buchdunger, Wood, Bold, Breier: "The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®)." in: International journal of oncology, Vol. 45, Issue 6, pp. 2267-77, (2014) (PubMed).

Target Details

Target: VEGF 165

Alternative Name: VEGF165

Background: Human Vascular Endothelial Growth Factor VEGF165, a 23 kDa protein consisting of 165 amino acid residues, is produced as a homodimer. VEGF is a polypeptide growth factor and a member of the platelet-derived growth factor family. It is a specific mitogen for vascular endothelial cells and a strong angiogenic factor in vivo. Two high-affinity tyrosine kinase receptors for VEGF165 have been identified, VEGFR-1 (FLT-1), and VEGFR-2 (KDR). Consistent with the endothelial cell-specific action of VEGF165, expression of both receptor genes has been found predominantly but not exclusively on endothelial cells. Expression of VEGFR-1 was also found on human monocytes, neutrophils (PMNs), bovine brain pericytes and villous and extra villous trophoblast. In addition to its action as a mitogen it is a potent vascular permeability factor (VPF) in vivo. VEGF165 is also a chemo attractant molecule for monocytes and endothelial cells. 5 different proteins are generated by differential splicing: VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206. The most abundant form is VEGF165. Whereas VEGF121 and VEGF165 are secreted proteins, VEGF145, VEGF189 and VEGF206 are strongly cell-associated. The isoforms VEGF145, VEGF165 and VEGF189 bind to heparin with high affinity. VEGF165 is apparently a homo-dimer, but preparations of VEGF165 show some heterogeneity on SDS gels, depending on the secretion of different glycosylation patterns. All dimeric forms have similar biological activities but their bioavailability is very different. There is good evidence that different cells and tissues express different VEGF isoforms. The other members of this increasing growth factor family are VEGF-B, -C, -D and -E. Another member is the Placenta growth factor PlGF.
Synonyms: vascular endothelial growth factor A, VEGFA, VPF, VEGF, MVCD1

Molecular Weight: 38.2 kDa

NCBI Accession: NM_001171626, NP_001165097

UniProt: P15692